Show simple item record

dc.contributor.authorPrekovic, S
dc.contributor.authorVan den Broeck, T
dc.contributor.authorMoris, L
dc.contributor.authorSmeets, E
dc.contributor.authorClaessens, F
dc.contributor.authorJoniau, S
dc.contributor.authorHelsen, C
dc.contributor.authorAttard, G
dc.date.accessioned2018-02-16T09:30:47Z
dc.date.issued2018-02
dc.identifier.citationMolecular and cellular endocrinology, 2018, 462 (Pt A), pp. 56 - 63
dc.identifier.issn0303-7207
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1156
dc.identifier.eissn1872-8057en_US
dc.identifier.doi10.1016/j.mce.2017.08.020en_US
dc.description.abstractProstate cancer progression and treatment relapse is associated with changes in the androgen receptor axis, and analysis of alternations of androgen receptor signaling is valuable for prognostics and treatment optimization. The profile of androgen receptor axis is currently obtained from biopsy specimens, which are not always easy to obtain. Moreover, the information acquired only provides a snapshot of the tumor biology, with strict spatial and temporal limitations. On the other hand, circulation is easily accessible source of both circulating tumor cells and circulating tumor DNA, which can be sampled at numerous time points. This Review will explore the potential use of androgen receptor axis alternations detectable in the blood in therapeutic decision-making and precision medicine for advancing metastatic castration-resistant prostate cancer.
dc.formatPrint-Electronic
dc.format.extent56 - 63
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectReceptors, Androgen
dc.subjectPrognosis
dc.subjectGene Dosage
dc.subjectMale
dc.subjectMolecular Targeted Therapy
dc.subjectLiquid Biopsy
dc.titleTreatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-08-31
rioxxterms.versionofrecord10.1016/j.mce.2017.08.020
rioxxterms.licenseref.startdate2018-02en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfMolecular and cellular endocrinology
pubs.issuePt A
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume462en_US
pubs.embargo.termsNot known
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorAttard, Gerhardten
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record